Insider Selling: Phreesia, Inc. (NYSE:PHR) CEO Sells $77,541.12 in Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,392 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $22.86, for a total value of $77,541.12. Following the sale, the chief executive officer now directly owns 1,222,005 shares of the company’s stock, valued at $27,935,034.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Chaim Indig also recently made the following trade(s):

• On Monday, April 8th, Chaim Indig sold 12,043 shares of Phreesia stock. The shares were sold at an average price of $22.62, for a total value of $272,412.66.

Phreesia Trading Down 4.2 %

Shares of NYSE PHR opened at $21.67 on Friday. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $34.98. The business has a 50-day simple moving average of $24.28 and a two-hundred day simple moving average of $21.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.78 and a current ratio of 1.78.

Phreesia (NYSE:PHR) last issued its earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The business had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. During the same quarter last year, the company earned ($0.72) EPS. The firm’s revenue was up 24.0% compared to the same quarter last year. On average, equities analysts predict that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Raymond James reaffirmed an “outperform” rating and set a $30.00 target price (up from $25.00) on shares of Phreesia in a research report on Friday, March 15th. Canaccord Genuity Group raised their target price on Phreesia from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Stephens reiterated an “overweight” rating and set a $28.00 price target on shares of Phreesia in a research note on Friday, March 22nd. JMP Securities increased their price target on Phreesia from $28.00 to $30.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 21st. Finally, Barclays started coverage on Phreesia in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $29.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.62.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. State of Wyoming boosted its stake in Phreesia by 34.6% in the 2nd quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after purchasing an additional 493 shares during the period. American International Group Inc. boosted its position in shares of Phreesia by 2.3% during the 4th quarter. American International Group Inc. now owns 26,342 shares of the company’s stock valued at $610,000 after acquiring an additional 591 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Phreesia by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,545 shares of the company’s stock valued at $637,000 after acquiring an additional 710 shares during the last quarter. Capital Impact Advisors LLC boosted its position in shares of Phreesia by 4.2% during the 4th quarter. Capital Impact Advisors LLC now owns 21,262 shares of the company’s stock valued at $688,000 after acquiring an additional 851 shares during the last quarter. Finally, Captrust Financial Advisors boosted its position in shares of Phreesia by 154.6% during the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock valued at $36,000 after acquiring an additional 866 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.